Opinion
SSA Positivity as Predictor of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder
Roberto Alejandro Cruz*1, Alexander B Ramos2, Bridget A Bagert3 and Jesus F Lovera4
1Dell Medical School, at the University of Texas, USA
2Louisiana Healthcare Science Center at New Orleans, USA
3Ochsner Clinic Foundation, New Orleans, USA
4Louisiana Healthcare Science Center at New Orleans, USA
Roberto Alejandro Cruz, Dell Medical School, at the University of Texas, USA.
Received Date: December 06, 2019; Published Date: December 16, 2019
Abstract
Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune astrocytopathy that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG) [1]. This central nervous system (CNS) inflammatory syndrome has specific core clinical characteristics, three common presentations include optic neuritis that can be bilateral with more severe visual impairment as compared with patients with multiple sclerosis, longitudinal extensive transverse myelitis (LETM) typically involving three or more vertebral segments, and area postrema syndrome characterized by intractable hiccups and intractable nausea & vomiting.
Keywords: Neuromyelitis optica spectrum disorder; Devic’s disease; Sjogren’s syndrome; Autoimmune diseases; NMOSD
-
Roberto Alejandro Cruz, Alexander B Ramos, Bridget A Bagertm Jesus F Lovera. SSA Positivity as Predictor of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder. Arch Neurol & Neurosci. 6(1): 2019. ANN.MS.ID.000626.
-
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.